Jeff Mihm serves as Noven’s Chief Executive Officer since January 2016, and was appointed to its Board of Directors in August 2016. Mr. Mihm has held senior leadership positions of increasing scope and importance since joining Noven in 2003. Most recently, he served as Vice President, Chief Administrative Officer & General Counsel, where he oversaw Noven’s Business Development, Corporate Affairs, Human Resources, Information Technology and Legal/Compliance functions. Prior to Noven, Mr. Mihm served as Senior Corporate Counsel to Panamerican Beverages, Inc. (at the time, one of the world’s largest Coca-Cola bottlers), and previously was a partner the law firm of Steel Hector & Davis (now part of Squire Patton Boggs).
John Choi is Noven’s Vice President, Chief Financial Officer and Treasurer. Mr. Choi, who joined Noven in 2010, most recently served Noven as its Executive Director – Business Planning & Analysis. Prior to Noven, Mr. Choi served as Director of Commercial Operations & Planning for Ther-Rx (a branded pharmaceutical division of KV Pharmaceuticals). Previously, he served Abbott Laboratories in various positions in the manufacturing operations, cost accounting, finance and international divisions, and served as an expatriate at Abbott’s Korean affiliate, where he held leadership roles in financial planning and analysis and other commercial leadership roles.
Patrick Gallagher joined Noven in February 2010 and serves as Vice President – Business Development. He has over 25 years’ experience in the pharmaceutical, biotechnology and drug delivery industries. Prior to joining Noven, he served as Senior Vice President, Business Development, Marketing & Sales at Acusphere. Previously, he served as Vice President, Corporate Business Development at Mylan Laboratories. Earlier, he held senior director positions at Bristol-Myers Squibb and Johnson & Johnson. As a corporate development and strategic planning consultant, he has also helped pharmaceutical, biotech and medical device industry clients develop and successfully execute critical business initiatives. Mr. Gallagher earned a B.Sc. degree from LaSalle University and an M.B.A. from The Wharton School of the University of Pennsylvania.
Michael Greene is Noven’s Vice President, General Counsel and Corporate Secretary. Mr. Greene previously served as Noven’s Deputy General Counsel & Executive Director – Alliance Management. From 2005 to 2010, Mr. Greene was an attorney at the law firm of Paul, Hastings, Janofsky & Walker, where he specialized in mergers and acquisitions (M&A) and other complex corporate transactions, including pharmaceutical industry transactions. Previously, he was an attorney with the law firm of Hunton & Williams specializing in M&A transactions and corporate law.
Mark Jackson joined Noven in February 2017 and serves as Vice President – Quality. Mr. Jackson has over 30 years’ experience in the pharmaceutical and medical device industries. He joined Noven from HeartWare, Inc., a global medical device company specializing in the treatment of heart failure, where he served as the Vice President of Quality and Design Assurance. Previously, Jackson was at Baxter Healthcare Corp where he held positions of increasing responsibility including, Vice President Medical Products Quality, Vice President Quality, Renal Division/Global Technical Service and Plant Manager.
Dr. Ralph Lipp joined Noven in October 2016 and serves as Vice President and Chief Scientific Officer. Dr. Lipp has more than 25 years of experience in transdermals and drug delivery including 14 years at Schering A.G., where he rose to the position of Head of Pharmaceutical Development. He also served as the Vice President Pharmaceutical Sciences R&D at Eli Lilly where he was responsible for successfully managing a portfolio of new chemical and biological entities plus life cycle management projects in all phases of clinical development. Dr. Lipp joins Noven from Lipp Life Sciences LLC, a firm he founded in 2012, which focused on advising clients in the areas of innovation strategy, innovation process, technology assessment, R&D portfolio review, and marketed products. He has more than 130 publications in the area of pharmaceutical science and drug delivery, including over 20 patents covering five marketed medicines. Dr. Lipp earned his Ph.D. in Medicinal Chemistry from Freie Universität Berlin in Berlin, Germany.
Yoshihiro Maegawa joined Noven in April 2015 and was appointed Noven’s Vice President – Hisamitsu Group Strategy & Planning in April 2016. Prior to this appointment, he served as Senior Advisor – Hisamitsu Affairs. Mr. Maegawa has over 22 years’ experience in the pharmaceutical industry. Previously, he served Hisamitsu Pharmaceutical Co., Inc. in a variety of functions including Corporate Planning, Marketing and Sales.
Krista Roberts joined Noven in June 2014 and serves as Vice President – Operations. She has over 15 years’ experience in the pharmaceutical and medical device industries. Prior to joining Noven, Ms. Roberts held various positions within Baxter International, serving most recently as Plant Manager of Baxter’s 600+ person manufacturing facility in Cleveland, Mississippi. Her prior roles at Baxter included Director of Manufacturing, Manufacturing Manager, Manufacturing Superintendent, Department Engineer, and Manufacturing Supervisor.
Specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products.
Year of Incorporation:
Chief Executive Officer:
Media, General Business
& Other Inquiries:
Partnering and Other Business Development Opportunities
Sunshine Act Inquiries:
Manager – Recruiting
Community Support:Corporate Social Responsibility
Noven is a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc. – bringing the benefits of patch therapy to patients around the world.